Just another example of my government saying one thing and doing the complete opposite and it’s suppose to be all fine and dandy. Stop slapping us in our face America!

Apologies if this has been discussed previously, I did a search but most results were for sativex and other synthetics and not an outright patent.

marijuana download growing guide

http://www.patentstorm.us/patents/6630507.html

Patent 6630507 Issued on October 7, 2003. Estimated Expiration Date: Icon_subject February 2, 2021

Inventors

Hampson, Aidan J.
Axelrod, Julius
Grimaldi, Maurizio

Assignee

The United States of America as represented by the Department of Health and Human Services

Application
No. 09/674028 filed on 02/02/2001

US Classes:
514/454

Examiners
Primary: Weddington, Kevin E.

Attorney, Agent or Firm

Klarquist Sparkman, LLP

International Class
A61K 31/35 (20060101)

Abstract
Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3. ##STR1##

Other References

Windholz et al., The Merck Index, Tenth Edition (1983) p. 241, abstract No. 1723.
Mechoulam et al., “A Total Synthesis of d1-?1 -Tetrahydrocannabinol, the Active Constituent of Hashish1,” Journal of the American Chemical Society, 87:14:3273-3275 (1965)
Mechoulam et al., “Chemical Basis of Hashish Activity,” Science, 18:611-612 (1970)
Ottersen et al., “The Crystal and Molecular Structure of Cannabidiol,” Acta Chem. Scand. B 31, 9:807-812 (1977)
Cunha et al., “Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients1,” Pharmacology, 21:175-185 (1980)
Consroe et al., “Acute and Chronic Antiepileptic Drug Effects in Audiogenic Seizure-Susceptible Rats,” Experimental Neurology, Academic Press Inc., 70:626-637 (1980)
Turkanis et al., “Electrophysiologic Properties of the Cannabinoids,” J. Clin. Pharmacol., 21:449S-463S (1981)
Carlini et al., “Hypnotic and Antielpileptic Effects of Cannabidiol,” J. Clin. Pharmacol., 21:417S-427S (1981)
Karler et al., “The Cannabinoids as Potential Antiepileptics,” J. Clin. Pharmacol., 21:437S-448S (1981)
Consroe et al., “Antiepileptic Potential of Cannabidiol Analgos,” J. Clin. Pharmacol., 21:428S-436S (1981)
Colasanti et al., “Ocular Hypotension, Ocular Toxicity,a nd Neurotoxicity in Response to Marihuana Extract and Cannabidiol,” Gen Pharm., Pergamon Press Ltd., 15(6):479-484 (1984)
Colasanti et al., “Intraocular Pressure, Ocular Toxicity and Neurotoxicity after Administration of Cannabinol or Cannabigerol,” Exp. Eye Res., Academic Press Inc., 39:251-259 (1984)
Volfe et al., “Cannabinoids Block Release of Serotonin from Platelets Induced by Plasma frm Migraine Patients,” Int. J. Clin. Pharm. Res., Bioscience Ediprint Inc., 4:243-246 (1985)
Agurell et al., “Pharmacokinetics and Metabolism of ?1 -Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*,” Pharmacological Reviews, 38(1):21-43 (1986)
Karler et al., “Different Cannabinoids Exhibit Different Pharmacological and Toxicological Properties,”NIDA Res. Monogr., 79:96-107 (1987)
Samara et al., “Pharmacokinetics of Cannabidiol in Dogs,” Drug Metabolism and Disposition, 16(3):469-472 (1988)
Choi, “Glutamate Neurotoxicity and Diseases of the Nervous System,” Neuron, Cell Press, 1:623-634 (1988)
Eshhar et al., “Neuroprotective and Antioxidant Activities of HU-211, A Novel NMDA Receptor Antagonist,” European Journal of Pharmacology, 283:19-29 (1995)
Skaper et al., “The ALIAmide Palmitoylethanolamide and Cannabinoids, but not Anandamide, are Protective in a Delayed Postglutamate Paradigm of Excitotoxic Death in Cerebellar Granule Neurons,” Neurobiology, Proc. Natl. Acad. Sci. USA, 93:3984-3989 (1996)
Alonso et al., “Simple Synthesis of 5-Substituted Resorcinols: A Revisited Family of Interesting Bioactive Molecules,” J. Org. Chem., American Chemical Society, 62(2):417-421 (1997)
Combes et al. “A Simple Synthesis of the Natural 2,5-Dialkylresorcinol Free Radical Scavenger Antioxidant: Resorstation,” Synthetic Communications, Marcel Dekker, Inc., 27(21):3769-3778 (1997)
Shohami et al., “Oxidative Stress in Closed-Head Injury: Brain Antioxidant Capacity as an Indicator of Functional Outcome,” Journal of Cerebral Blood Flow and Metabolism, Lippincott-Raven Publishers, 17(10):1007-1019 (1997)
Zurier et al., “Dimethylheptyl-THC-11 OIC Acid,” Arthritis Rheumatism, 41(1):163-170 (1998)
Hampson et al., “Dual Effects of Anandamide on NMDA Receptor-Mediated Responses and Neurotransmission,” Journal of Neurochemistry, Lippincott-Raven Publishers, 70(2):671-676 (1998)
Hampson et al., “Cannabidiol and (-)?9 -tetrahydrocannabiono are Neuroprotective Antioxidants,” Medical Sciences, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998)